argenx stock reports 60 percent Q2 sales growth now

Published on 09/28/2026 at 13:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

argenx stock carried USD 7.32 in Q2 adjusted EPS versus USD 5.86 expected. MarketBeat cited a USD 1,158.61 average target from 24 analysts.

Fotorealistisches Laborpanorama: Wissenschaftler in weißen Kitteln begutachten leuchtende Antikörper-3D-Modelle auf Bildschirmen, Stahltische mit Laborgeräten im Hintergrund — Argenx NL0010832176 Forscher analysieren im modernen Biopharma-Labor leuchtende Antikörper-Strukturen auf großen Monitoren, Illustration mit AI erstellt.

argenx (ISIN NL0010832176) was last at USD 959.49 on Nasdaq on September 25, 2026 at 4:00 p.m. ET, down 0.28 percent from the prior close. The company enters the final quarter with Q2 product net sales of USD 1.5 billion, while analyst consensus still points to an average 12-month target of USD 1,158.61.

Q2 sales reached USD 1.5 billion

According to Yahoo Finance on July 23, 2026, product net sales rose 60 percent year over year and 17 percent quarter over quarter in Q2 2026. Operating profit reached USD 494 million, up 146 percent year over year, showing that the revenue expansion translated into stronger operating leverage.

The earnings mix also exceeded expectations. MarketBeat reported on September 9, 2026, that quarterly EPS reached USD 7.32 versus a USD 5.86 consensus estimate, a USD 1.46 beat. Revenue was USD 1.54 billion against a USD 1.45 billion forecast.

Analysts see further upside

MarketBeat said on September 9, 2026, that 24 analysts assigned argenx a Moderate Buy consensus. Seventeen analysts recommended buying the stock, two issued strong-buy ratings and five recommended holding it. The average target of USD 1,158.61 stands 20.75 percent above the Nasdaq price of USD 959.49.

The latest company discussion also highlighted execution risks alongside the growth. The July 23 call described two registrational readouts before year-end, including myositis and empasiprubart programs, making clinical delivery an important counterpart to the commercial strength of VYVGART.

argenx stock remains below its high

argenx stock was last at USD 959.49 on Nasdaq on September 25, 2026 at 4:00 p.m. ET. The 52-week range was USD 661.85 to USD 1,072.75, daily volume was 264,380 shares and market capitalization was USD 59.7 billion.